Mirae Asset Global Investments Co. Ltd. Acquires 32,022 Shares of Elanco Animal Health Incorporated $ELAN

Mirae Asset Global Investments Co. Ltd. bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the third quarter, HoldingsChannel.com reports. The firm bought 32,022 shares of the company’s stock, valued at approximately $717,000.

A number of other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Elanco Animal Health in the 2nd quarter valued at about $1,202,198,000. Primecap Management Co. CA acquired a new position in shares of Elanco Animal Health during the second quarter worth about $1,118,402,000. State Street Corp grew its holdings in shares of Elanco Animal Health by 4.7% during the second quarter. State Street Corp now owns 16,063,046 shares of the company’s stock worth $395,312,000 after buying an additional 726,567 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Elanco Animal Health during the second quarter worth about $205,636,000. Finally, Sei Investments Co. grew its holdings in shares of Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after buying an additional 4,975,721 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Jefferies Financial Group downgraded shares of Elanco Animal Health from a “buy” rating to a “hold” rating and lowered their price objective for the company from $31.00 to $24.00 in a report on Tuesday, October 20th. UBS Group lifted their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Morgan Stanley cut their price objective on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.33.

Elanco Animal Health Trading Down 0.4%

Elanco Animal Health stock opened at $25.65 on Monday. The company has a market cap of $12.81 billion, a price-to-earnings ratio of -85.48, a P/E/G ratio of 2.28 and a beta of 1.73. The firm has a 50-day moving average of $23.13 and a 200-day moving average of $23.82. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a one year low of $19.40 and a one year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. Elanco Animal Health had a positive return on equity of 8.83% and a negative net margin of 2.86%. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter in the previous year, the business earned $0.19 earnings per share. Elanco Animal Health’s quarterly revenue was up 11.3% on a year-over-year basis. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 1.13 earnings per share for the current fiscal year.

Key Stories Impacting Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Insider Buying and Selling

In other news, insider Timothy J. Bettington sold 4,350 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $23.00, for a total value of $100,050.00. Following the completion of the sale, the insider owned 138,911 shares of the company’s stock, valued at approximately $3,194,953. This represents a 3.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lawrence Kurzius acquired 40,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was bought at an average cost of $23.40 per share, with a total value of $936,000.00. Following the acquisition, the director owned 188,647 shares in the company, valued at $4,414,339.80. The trade was a 26.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 48,998 shares of company stock worth $1,139,373 over the last 90 days. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.